Clarity Pharmaceuticals announced that 50 patients have now been imaged with (64) Cu-SAR-Bombesin in its United States-based diagnostic trial, SABRE (NCT05407311), for participants with PSMA-negative prostate cancer. SABRE, which derives from "Copper-64 SAR-Bombesin in Biochemical Recurrence of prostate cancer" is a Phase II Positron Emission Tomography (PET) imaging trial of participants with PSMA-negative biochemical recurrence (BCR) of prostate cancer following definitive therapy. It is a multi-centre, single arm, non-randomised, open-label trial of (64) Cu-labelled SAR-Bombesin.

The primary objectives of the trial are to investigate the safety and tolerability of the product as well as its ability to correctly detect recurrence of prostate cancer.